Increased mortality in patients with differentiated thyroid cancer associated with graves' disease.Pellegriti G, Mannarino C, Russo M, Terranova R, Marturano I, Vigneri R, Belfiore A. J Clin Endocrinol Metab. 2013 Mar;98(3):1014-21 We previously reported that differentiated thyroid cancer (DTC) has higher aggressiveness and poorer prognosis in patients with Graves' disease (GD) than DTC in euthyroid […]
Read more »Recent Posts
CHILDHOOD OBESITY FOSTERS ANTITHYROID IMMUNITY??
Childhood weight gain and thyroid autoimmunity at age 60-64 years: the 1946 british birth cohort study.Ong KK, Kuh D, Pierce M, Franklyn JA. J Clin Endocrinol Metab. 2013 Apr;98(4):1435-42. doi: 10.1210/jc.2012-3761 Complex bidirectional relationships have been described between body weight, thyroid function, and risk of thyroid disorders, including thyroid autoimmunity. We used a life-course approach […]
Read more »MORE ON LOW VS HIGH DOSE 131-I ABLATION
Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, Wang H. J Clin Endocrinol Metab. 2013 Apr;98(4):1353-60. doi: 10.1210/jc.2012-3682. There is uncertainty over the dose of (131)I required for thyroid remnant ablation.: The aim of this study was to assess […]
Read more »IGF-1 Receptor antibodies in GO
Autoantibodies to the IGF1 Receptor in Graves' Orbitopathy.Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Köhrle J, Eckstein A, Schomburg L. J Clin Endocrinol Metab. 2013 Feb;98(2):752-60. doi: 10.1210/jc.2012-1771 Graves' disease (GD) is maintained by stimulating antibodies against the TSH receptor. Graves' orbitopathy (GO) is the main extrathyroidal manifestation of GD, potentially involving […]
Read more »SYNTHROID VS GENERICS, AGAIN- EQUIVALENT, OR NOT?? 24 Feb 2013
NO-Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS. J Clin Endocrinol Metab. 2013 Feb;98(2):610-7. doi: 10.1210/jc.2012-3125. In the United States, generic substitution of levothyroxine (l-T(4)) by pharmacists is permitted if the formulations are deemed to be bioequivalent by the Federal Drug […]
Read more »